[go: up one dir, main page]

MX2021002188A - Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende. - Google Patents

Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.

Info

Publication number
MX2021002188A
MX2021002188A MX2021002188A MX2021002188A MX2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A MX 2021002188 A MX2021002188 A MX 2021002188A
Authority
MX
Mexico
Prior art keywords
sub
pharmaceutical composition
same
amine derivative
heterocyclic amine
Prior art date
Application number
MX2021002188A
Other languages
English (en)
Inventor
Keuk Chan Bang
Yeon Im Lee
Deok Ki Eom
Joon Seok Park
Wol Young Kim
Youn Jung Yoon
Jaehyun Jung
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Priority claimed from PCT/KR2019/010894 external-priority patent/WO2020045941A1/ko
Publication of MX2021002188A publication Critical patent/MX2021002188A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a un nuevo derivado de amina heterocíclico representado por la siguiente fórmula química 1 y a una composición farmacéutica que lo comprende, y el compuesto de acuerdo con la presente divulgación puede usarse de manera útil para la prevención o el tratamiento de enfermedades autoinmunitarias o cánceres. Fórmula química 1 (ver Fórmula) en donde, en la fórmula química 1, R1, R2, X1, X2, L, Y, A y B son los mismos que los definidos en la memoria descriptiva.
MX2021002188A 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende. MX2021002188A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180100359 2018-08-27
KR1020190104641A KR102328682B1 (ko) 2018-08-27 2019-08-26 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
PCT/KR2019/010894 WO2020045941A1 (ko) 2018-08-27 2019-08-27 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
MX2021002188A true MX2021002188A (es) 2021-05-14

Family

ID=69802542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002188A MX2021002188A (es) 2018-08-27 2019-08-27 Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.

Country Status (21)

Country Link
US (1) US12227498B2 (es)
EP (2) EP4643954A2 (es)
JP (1) JP7162741B2 (es)
KR (1) KR102328682B1 (es)
CN (1) CN112638910B (es)
AU (1) AU2019331328B2 (es)
BR (2) BR122022001938B1 (es)
CA (1) CA3108856C (es)
CL (1) CL2021000421A1 (es)
CO (1) CO2021001849A2 (es)
DO (1) DOP2021000030A (es)
EC (1) ECSP21011232A (es)
MA (1) MA53507A (es)
MX (1) MX2021002188A (es)
MY (1) MY205156A (es)
PE (2) PE20251890A1 (es)
PH (1) PH12021550329A1 (es)
RU (1) RU2760184C1 (es)
SA (1) SA521421262B1 (es)
SG (1) SG11202101451QA (es)
TN (1) TN2021000025A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN114401722A (zh) * 2019-07-19 2022-04-26 布里奇恩生物科学公司 酪氨酸激酶的抑制剂
CN115151537B (zh) * 2020-02-26 2024-09-06 株式会社大熊制药 制备杂环胺衍生物的方法
KR20210124569A (ko) * 2020-04-03 2021-10-15 주식회사 하임바이오 암 치료를 위한 신규 화합물 및 이를 포함하는 조성물
CN114605404B (zh) * 2022-03-23 2024-01-05 合肥美诺医药有限公司 一种新型含噻唑类化合物、中间体及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DE3905763A1 (de) * 1989-02-24 1990-09-06 Bayer Ag Sulfonylierte azinyliminoheteroazole, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als herbizide
HUP0202682A3 (en) 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
ATE253561T1 (de) 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
ES2242771T5 (es) 2000-09-15 2011-10-14 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como inhibidores de proteína quinasas.
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US20060030016A1 (en) 2003-12-05 2006-02-09 Graham Cheetham Crystal structure of interleukin-2 tyrosine kinase (ITK) and binding pockets thereof
US20070032403A1 (en) 2003-12-30 2007-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Crystal structure of the ITK kinase domain
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
DE112007002257T5 (de) 2006-09-30 2009-07-30 TK Holdings, Inc., Armada Gaserzeugungsmittelzusammensetzungen
JP5282091B2 (ja) 2007-07-25 2013-09-04 ブリストル−マイヤーズ スクイブ カンパニー トリアジンキナーゼ阻害剤
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
AU2010259023A1 (en) 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
WO2011031896A2 (en) 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
RU2012114902A (ru) * 2009-09-16 2013-10-27 Авила Терапьютикс, Инк. Конъюгаты и ингибиторы протеинкиназы
US8759366B2 (en) 2009-12-17 2014-06-24 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
KR102121628B1 (ko) 2010-10-15 2020-06-17 스와겔로크 컴패니 페룰을 갖는 푸시 접속 도관 피팅
KR101682417B1 (ko) 2011-02-25 2016-12-06 주식회사유한양행 다이아미노피리미딘 유도체 및 그의 제조방법
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP3984997B1 (en) 2012-01-06 2025-07-30 Les Laboratoires Servier Therapeutically active compounds and their methods of use
JP2015526520A (ja) 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
US9586931B2 (en) * 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
CN104822663B (zh) 2012-10-04 2017-03-08 犹他大学研究基金会 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
MX2015014861A (es) 2013-05-01 2016-03-09 Hoffmann La Roche Pirimidinas sustituidas con heterocicloalquilo c-enlazado y sus usos.
WO2014181137A1 (en) 2013-05-10 2014-11-13 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
US10273224B2 (en) 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
AR098136A1 (es) 2013-10-21 2016-05-04 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
CN104628657A (zh) 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
KR20160122736A (ko) 2014-01-14 2016-10-24 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 이의 용도
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
WO2016065138A1 (en) * 2014-10-22 2016-04-28 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US20180193274A1 (en) 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
WO2016177347A1 (en) 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
KR102686957B1 (ko) 2016-11-08 2024-07-22 주식회사 대웅제약 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
CN111527091B (zh) 2017-12-28 2023-03-28 株式会社大熊制药 作为激酶抑制剂的氧基-氟哌啶衍生物
WO2020045941A1 (ko) 2018-08-27 2020-03-05 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
EP3894392A4 (en) 2018-12-11 2022-08-24 Duke University COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2020127200A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
CN115151537B (zh) 2020-02-26 2024-09-06 株式会社大熊制药 制备杂环胺衍生物的方法
WO2022071772A1 (ko) 2020-09-29 2022-04-07 (주)메디톡스 단백질 키나제 저해제 및 그의 용도
WO2022199599A1 (zh) 2021-03-23 2022-09-29 凯复(苏州)生物医药有限公司 丙烯酰基取代的化合物、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
RU2760184C1 (ru) 2021-11-22
EP4643954A2 (en) 2025-11-05
MY205156A (en) 2024-10-04
CA3108856A1 (en) 2020-03-05
CL2021000421A1 (es) 2021-07-23
CO2021001849A2 (es) 2021-02-26
CN112638910A (zh) 2021-04-09
SG11202101451QA (en) 2021-03-30
TN2021000025A1 (en) 2022-10-03
SA521421262B1 (ar) 2024-02-29
KR102328682B1 (ko) 2021-11-18
JP7162741B2 (ja) 2022-10-28
US20220064155A1 (en) 2022-03-03
AU2019331328B2 (en) 2022-03-17
EP3845530A1 (en) 2021-07-07
US12227498B2 (en) 2025-02-18
KR20200024111A (ko) 2020-03-06
PH12021550329A1 (en) 2021-10-04
BR112021003652B1 (pt) 2022-04-26
PE20210417A1 (es) 2021-03-04
EP3845530A4 (en) 2022-04-27
JP2021534256A (ja) 2021-12-09
BR112021003652A2 (pt) 2021-05-18
DOP2021000030A (es) 2021-05-31
CA3108856C (en) 2023-05-16
PE20251890A1 (es) 2025-07-25
ECSP21011232A (es) 2021-03-31
NZ772789A (en) 2024-09-27
AU2019331328A1 (en) 2021-03-11
CN112638910B (zh) 2024-06-11
MA53507A (fr) 2022-04-27
BR122022001938B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12020551572A1 (en) Heterocyclic compounds as immunomodulators
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
EP4365179A3 (en) Novel rapamycin derivatives
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
MX2010006421A (es) Compuestos organicos.
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
MX2021003427A (es) Nuevos oxadiazoles.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
PH12018502012A1 (en) Griseofulvin compound
MX2020000576A (es) Compuestos quimicos.
MX2021003430A (es) Nuevos oxadiazoles.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12019500198A1 (en) Compounds and compositions and uses thereof
WO2015042414A8 (en) Multicyclic compounds and methods of using same